⌘K
t
| Date | 5 Dec 2022 |
| Time | 07:00:04 |
| Category | Director/PDMR dealings |
| ID | 5208I |
Director Dealing
Guildford, UK - 5 December 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that on 2 December 2022, Richard Barfield, Chief Financial Officer of Ergomed, exercised options under the Company's Long Term Incentive Plan and sold the shares issued by the Company pursuant to such exercise. Mr Barfield exercised options over 125,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an exercise price of £0.01 per share and subsequently sold 125,000 Ordinary Shares at a price of £13.45 per share.
Following this sale, Richard Barfield holds 25,000 Ordinary Shares representing 0.05% of the Company's issued share capital.
The notification set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Richard Barfield |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Financial Officer |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Ergomed plc |
|
|
b) |
Legal Entity Identifier |
213800BVS8I9VMC1AP84 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 1 pence each
GB00BN7ZCY67 |
|
|
b) |
Nature of the transaction |
Exercise of share options under the Company's Long Term Incentive Plan |
|
|
c) |
Currency |
GBP
|
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
Exercise price £0.01 |
125,000 |
||
|
|
|
||
|
e) |
Aggregated information
- Aggregated volume
- Price
- Aggregated total |
n/a |
|
|
f) |
Date of the transaction |
2 December 2022 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Richard Barfield |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Financial Officer |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Ergomed plc |
|
|
b) |
Legal Entity Identifier |
213800BVS8I9VMC1AP84 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 1 pence each
GB00BN7ZCY67 |
|
|
b) |
Nature of the transaction |
Sale |
|
|
c) |
Currency |
GBP
|
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
£13.45 |
125,000 |
||
|
|
|
||
|
e) |
Aggregated information
- Aggregated volume
- Price
- Aggregated total |
125,000 £13.45 £1,681,250
|
|
|
f) |
Date of the transaction |
2 December 2022 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.